Joshua Richter, MD

Joshua Richter, MD, talks about the barriers to diversity in oncology clinical trials.

In an interview with Targeted Oncology, Joshua Richter, MD, discusses how community oncologists can help manage disparities in diversity in clinical trials.

Joshua Richter, MD, discusses the available combination therapies for patients with early relapsed/refractory multiple myeloma using anti-CD38 monoclonal antibodies.

Joshua Richter, MD, evaluates the efficacy and safety data of linvoseltamab for the treatment of patients with multiple myeloma.

Dr Srdan Verstovsek discusses how ruxolitinib might fit into the myelofibrosis treatment landscape in the future, and highlights remaining unmet needs.

Srdan Verstovsek, MD, reviews data presented at ASH 2022 on combination ruxolitinib and selinexor for the frontline treatment of myelofibrosis.

Dr Srdan Verstovsek, MD, details how the JAK-STAT pathway is utilized in the treatment of myelofibrosis.

Srdan Verstovsek, MD, provides an overview of myelofibrosis and the clinical signs and symptoms to look for.

Dr Joshua Richter explains which patients with multiple myeloma are most suitable for triplet combination therapies.

Joshua Richter, MD, highlights key data from an update to a study investigating a selinexor triplet combination therapy.

Dr Joshua Richter explains triple class refractory myeloma and the need for more data on treatment options.

Joshua Richter, MD, reviews data from two clinical trials investigating selinexor combination therapies for the treatment of multiple myeloma.

Dr Joshua Richter describes the mechanism of action of XPO1 inhibitor selinexor and its use in treating multiple myeloma.

Joshua Richter, MD, gives an overview of relapse/refractory multiple myeloma and the available treatment options.

Joshua Richter, MD, provides insight on the impact of the addition of daratumumab to treatments for patients with multiple myeloma.

A 78-year-old White woman was given a diagnosis of stage II multiple myeloma and was deemed transplant ineligible. Genetic testing showed deletion 17p.

Joshua Richter, MD, Hackensack University Medical Center, discusses a tool which explored the incidence and survival impact of self-reported symptoms and psychologic distress among patients with multiple myeloma during the 2017 ASH Annual Meeting.